This is a summary of the European public assessment report (EPAR) for Vedrop. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vedrop. For practical information about using Vedrop, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Vedrop is indicated in vitamin-E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region.
Therapeutic Area (MeSH)
N/AATC Code
A11HA08
ATC Item
tocofersolan
Pharmacotherapeutic Group
Vitamins
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| tocofersolan | N/A | 托可索仑 |
EMA Name
Vedrop
Medicine Name
Vedrop
Aliases
N/ANo risk management plan link.
